antirejection


Also found in: Medical.

an·ti·re·jec·tion

 (ăn′tē-rĭ-jĕk′shən, ăn′tī-)
adj.
Preventing rejection of a transplanted tissue or organ.

antirejection

(ˌæntɪrɪˈdʒɛkʃən)
adj
acting to prevent the rejection of a transplanted organ

an•ti•re•jec•tion

(ˌæn ti rɪˈdʒɛk ʃən, ˌæn taɪ-)
adj.
preventing the rejection of a transplanted organ: antirejection drugs.
[l965–70]
References in periodicals archive ?
"Second, I would suggest additional experimentation, using alternative antirejection methods, such as the transplantation of donor bone marrow, which may encourage the body to be more accepting of such a large transplant in another region of the body.
Graham was put on a stronger dose of antirejection drugs and was recovering at home until last Tuesday, when he was taken into Liverpool's Alder Hey hospital after not eating for several days.
The recipient was given antirejection pills, but nine days after the operation the body rejected the womb.
With new antirejection drugs, the only requirement is that blood types are the same.
The high cost of antirejection medications and the lack of insurance coverage was an issue for some family members, however, these factors didn't decrease their hopes for a transplant.
But the pharmaceutical industry worked and discovered an antirejection medicine to overcome that hurdle.
CSA, an important component of most antirejection immunosuppressive regimens, is however, a difficult drug to use optimally.
Corneas are the most commonly transplanted tissues, but they are attacked by the immune systems of at least 10 percent of the people who receive them--despite topical antirejection drugs.
A patient who refuses to take antirejection medications has exempted himself from organ transplant.
Even with improved surgical techniques and better antirejection drugs, the single-lung replacement has not been beneficial to many individuals with advanced COPD because the person's remaining lung often steals too much of the blood needed for aeration of the lungs, and also serves as a haven for disease-causing microorganisms.
Terasaki and colleagues demonstrated that a decrease in HLA antibody levels can be used as a surrogate marker for the efficacy of an antirejection treatment and directly correlates with superior allograft survival [16].
The patient did not experience any acute rejection during follow-up and no antirejection therapy was required.